Emerging role of immune checkpoint inhibitors in hepatocellular carcinoma

Vito Longo, Oronzo Brunetti, Antonio Gnoni, Antonella Licchetta, Sabina Delcuratolo, Riccardo Memeo, Antonio Giovanni Solimando, Antonella Argentiero

Research output: Contribution to journalReview article

Abstract

Hepatocellular carcinoma is the most common primary liver cancer and the fourth leading cause of cancer death worldwide. A total of 70–80% of patients are diagnosed at an advanced stage with a dismal prognosis. Sorafenib had been the standardcare for almost a decade until 2018 when the Food and Drug Administration approved an alternative first-line agent namely lenvatinib. Cabozantinib, regorafenib, and ramucirumab also displayed promising results in second line settings. FOLFOX4, however, results inan alternative first-line treatment for the Chineseclinical oncology guidelines. Moreover,nivolumab and pembrolizumab,two therapeutics against the Programmed death (PD)-ligand 1 (PD-L1)/PD1 axis have been recently approvedfor subsequent-line therapy. However, similar to other solid tumors, the response rate of single agent targeting PD-L1/PD1 axis is low. Therefore, a lot of combinatory approaches are under investigation, including the combination of different immune checkpoint inhibitors (ICIs), the addition of ICIs after resection or during loco-regional therapy, ICIs in addition to kinase inhibitors, anti-angiogenic therapeutics, and others. This review focuses on the use of ICIs for the hepatocellular carcinoma with a careful assessmentof new ICIs-based combinatory approaches.

Original languageEnglish
Article numberE698
JournalMedicina (Lithuania)
Volume55
Issue number10
DOIs
Publication statusPublished - Oct 2019

Keywords

  • HCC
  • Hepatocellular carcinoma
  • Immune checkpoint inhibitors
  • Immune microenvironment
  • Nivolumab
  • Pembrolizumab
  • Targeted therapies

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Emerging role of immune checkpoint inhibitors in hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this